Q-omics provides the consensus-scored MIR133B profile across patient tissues and cancer cell-line models. MIR133B expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MIR133B is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, MIR133B RNA expression shows 6,474 significant gene co-expression associations, with the highest sampling consensus in UCS. Together, these results highlight BLCA, KIRC, and UCS as cancer lineages where MIR133B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR133B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR133B survival associations across molecular data types. MIR133B RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR133B RNA expression–survival associations across cancer types. High MIR133B expression shows unfavorable associations in BLCA, BRCA, MESO, TGCT, STAD and OV. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MIR133B RNA expression.
This table summarizes MIR133B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR133B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR133B shows lower tumor expression in KIRC and HNSC. The KIRC box plot shows higher MIR133B RNA expression in normal versus tumor tissue (log2 FC = −0.104, t-test p = .001).
This table shows molecular features associated with MIR133B in patient tissues and cancer cell lines. In patient samples, MIR133B shows the broadest associations at the RNA and protein expression levels, with UCS recurring as the lineage with the largest associated feature set.
